Peptide Comparison
Follistatin 344 vs Follistatin 315
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Follistatin 344 and Follistatin 315 share the myostatin-inhibitor class and carry roughly equivalent evidence (Preclinical / Preclinical). On the catalogued data layer Follistatin 344 has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Follistatin 344's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Follistatin 344 | Follistatin 315 | |
|---|---|---|
| Class | Follistatin isoform; anabolic | Follistatin isoform; anabolic |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | Tissue-bound follistatin precursor; local myostatin inhibition | Circulating follistatin; heparin-binding; systemic myostatin inhibition |
| Route | SC injection | SC injection |
| Half-life | ~hours | ~hours |
| Dosage (research) | 100-500 mcg SC daily | 100-500 mcg SC daily |
| Evidence tier | Preclinical | Preclinical |
| Research depth | 32 indexed | 75 indexed |
| Availability | Research Chemical | Research Chemical |
| Reported risks | Same as Follistatin; limited data | Reproductive hormone interference |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Follistatin 344 or Follistatin 315?
Follistatin 344 and Follistatin 315 share the myostatin-inhibitor class and carry roughly equivalent evidence (Preclinical / Preclinical). On the catalogued data layer Follistatin 344 has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Follistatin 344's evidence base is currently denser.
What is the difference between Follistatin 344 and Follistatin 315?
Follistatin 344 is classed as Follistatin isoform; anabolic; Follistatin 315 is classed as Follistatin isoform; anabolic. Reported mechanism: Follistatin 344, Tissue-bound follistatin precursor; local myostatin inhibition; Follistatin 315, Circulating follistatin; heparin-binding; systemic myostatin inhibition. Reported half-life: Follistatin 344, ~hours; Follistatin 315, ~hours. Routes in published studies: Follistatin 344, SC injection; Follistatin 315, SC injection.
Which has stronger evidence, Follistatin 344 or Follistatin 315?
Follistatin 344 and Follistatin 315 sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Follistatin 344 is graded Preclinical, with 2 cited sources on its reference page and 32 indexed studies. Follistatin 315 is graded Preclinical, with 1 cited source on its reference page and 75 indexed studies.
Which is more accessible, Follistatin 344 or Follistatin 315?
Neither Follistatin 344 nor Follistatin 315 is an FDA-approved drug. Catalog status: Follistatin 344, Research Chemical; Follistatin 315, Research Chemical.
Are Follistatin 344 and Follistatin 315 ever combined?
Follistatin 344 and Follistatin 315 appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…